IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IDYA IDEAYA Biosciences

已收盘 10-09 16:00:00 EDT

36.11

+0.05

+0.14%

盘后36.11

+0.000.00%

19:30 EDT

最高36.72	最低35.94	成交量69.91万
今开35.94	昨收36.06	日振幅2.16%
总市值34.76亿	流通市值34.08亿	总股本9,627万
成交额2,530万	换手率0.74%	流通股本9,437万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IDYA","market":"US","secType":"STK","nameCN":"IDEAYA Biosciences","latestPrice":36.11,"timestamp":1791576000000,"preClose":36.06,"halted":0,"volume":699094,"hourTrading":{"tag":"盘后","latestPrice":36.11,"preClose":36.11,"latestTime":"19:30 EDT","volume":18736,"amount":676464.9,"timestamp":1791588606683,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0013865779256793443,"floatShares":94374456,"shares":96274800,"eps":-1.956123,"marketStatus":"已收盘","change":0.05,"latestTime":"10-09 16:00:00 EDT","open":35.94,"high":36.72,"low":35.94,"amount":25301106.700319998,"amplitude":0.021631,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.956123,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":5,"adr":0,"listingDate":1558584000000,"exchange":"NASDAQ","adjPreClose":36.06,"preHourTrading":{"tag":"盘前","latestPrice":36.05,"preClose":36.06,"latestTime":"08:23 EDT","volume":250,"amount":9012.5,"timestamp":1791548613310,"change":-0.01,"changeRate":-0.000277,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":36.11,"preClose":36.11,"latestTime":"19:30 EDT","volume":18736,"amount":676464.9,"timestamp":1791588606683,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.1131,"impliedVol":1.4272,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/IDYA","defaultTab":"news","newsList":[{"id":"1127062433","title":"IDEAYA Biosciences与Servier联合宣布：Darovasertib联合Crizotinib辅助治疗葡萄膜黑色素瘤全球III期注册临床试验Optimum-11完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1127062433","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127062433?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:03","pubTimestamp":1788948197,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences与Servier今日共同宣布，评估Darovasertib联合Crizotinib作为葡萄膜黑色素瘤辅助治疗方案的全球III期注册临床试验Optimum-11，已顺利完成首例患者给药。Darovasertib作为一种新型口服蛋白激酶C抑制剂，与Crizotinib这一多靶点酪氨酸激酶抑制剂联用，展现出针对这一罕见肿瘤类型的协同抗肿瘤潜力。IDEAYA Biosciences与Servier对此次合作充满信心。双方认为，Optimum-11这一注册性研究如能获得积极结果，将有望为高风险葡萄膜黑色素瘤患者提供一种新的治疗选择，填补当前辅助治疗领域的空白。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119801270","title":"Ideaya Biosciences宣布：IDE849（DLL3 Top1 ADC）获FDA Type C会议积极反馈，III期注册性试验设计有望支持广泛期小细胞肺癌的加速及全面批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1119801270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119801270?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:01","pubTimestamp":1788170479,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日宣布，已成功完成与美国食品药品监督管理局的Type C会议，就其在研药物IDE849的III期注册性试验设计达成共识。此次FDA反馈意义重大，为IDE849在广泛期小细胞肺癌患者中潜在获得加速批准及后续全面批准铺平了道路。该公司表示，FDA对提出的关键性试验设计持积极态度，该设计旨在同时支持加速审批与常规审批双轨路径。IDEAYA正积极布局这一高度未满足需求的领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197034181","title":"IDEAYA Biosciences：计划于2026年下半年启动与罗氏RG6505联合治疗的1期临床队列，针对MTAP缺失及RAS突变型胰腺导管腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1197034181","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197034181?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:03","pubTimestamp":1787133786,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，其计划在2026年下半年启动一项1期联合治疗队列研究。该研究将评估IDEAYA在研药物与罗氏旗下RG6505的组合疗法，目标适应症为MTAP基因缺失且携带RAS突变的胰腺导管腺癌。这一临床布局标志着IDEAYA在肿瘤精准医疗领域的又一关键推进。IDEAYA方面暂未披露更多关于该队列的具体剂量方案或患者招募细节，但此次与罗氏的合作无疑将为双方在肿瘤免疫联合疗法领域积累宝贵的数据与经验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159671526","title":"IDEAYA Biosciences宣布与Genentech达成临床合作，聚焦MTAP缺失型KRAS G12d突变胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1159671526","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159671526?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:01","pubTimestamp":1787133683,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日宣布，已与Genentech达成一项临床合作，双方将携手推进针对MTAP缺失型KRAS G12d突变胰腺癌的联合研究。这一合作聚焦于特定基因组背景下的胰腺癌患者群体——即同时存在MTAP基因缺失与KRAS G12d突变的病例。IDEAYA Biosciences表示，此次与Genentech的联手，旨在探索新型联合治疗策略，以应对这一难治性癌症亚型中未被满足的临床需求。IDEAYA Biosciences与Genentech此次的临床协作，或将推动这一细分领域的治疗格局发生转变。市场对此消息反应积极，IDEAYA Biosciences股价在公告后出现波动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169026792","title":"IDEAYA Biosciences宣布IDE892——有望成为同类最佳MTA协同PRMT5抑制剂——启动MTAP缺失胰腺癌和肺癌1/2期研究第二部分单药扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1169026792","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169026792?lang=zh_cn&edition=full","pubTime":"2026-07-27 18:01","pubTimestamp":1785146471,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日正式宣布，其候选药物IDE892——一种被视作具有“同类最佳”潜力的MTA协同PRMT5抑制剂——已启动1/2期临床研究的第二部分单药扩展阶段。该研究聚焦于MTAP基因缺失的胰腺癌和肺癌患者。此次启动的单药扩展部分，将在一系列经过严格筛选的MTAP缺失肿瘤患者中，进一步评估IDE892的安全性、耐受性及初步抗肿瘤活性。IDEAYA公司表示，基于前期临床数据，IDE892展现出令人鼓舞的潜力，有望改变当前MTAP缺失癌症的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193372500","title":"IDEAYA Biosciences 宣布拟进行高达3亿美元的普通股及预融资权证公开发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1193372500","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193372500?lang=zh_cn&edition=full","pubTime":"2026-06-09 04:02","pubTimestamp":1780948937,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 宣布，公司计划进行一项公开发行，预计募集资金总额最高可达3亿美元。此次发行将包含公司普通股以及与之配套的预融资权证。\n此举旨在为公司后续的研发活动及一般运营提供资金支持。具体的发行条款，包括发行的股票数量、权证条款及最终定价，将根据市场状况及其他因素最终确定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102086458","title":"IDEAYA Biosciences宣布与罗氏在MTAP缺失型RAS突变胰腺癌领域达成临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1102086458","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102086458?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:00","pubTimestamp":1780480823,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，已与罗氏就针对MTAP缺失型RAS突变胰腺癌的联合疗法开发达成临床合作。此项合作旨在探索IDEAYA的靶向疗法与罗氏的相关疗法相结合，为这一难治性癌症亚型患者开发新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103177449","title":"IDEAYA Biosciences公布截至2026年3月31日持有约9.73亿美元现金及证券 资金可支撑运营至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1103177449","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103177449?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:17","pubTimestamp":1777976237,"startTime":"0","endTime":"0","summary":"生物科技公司IDEAYA Biosciences（股票代码：IDYA）最新财务数据显示，截至2026年3月31日，公司持有的现金及证券总额约为9.73亿美元。这一资金规模足以支持公司运营至2030年，资金续航时间与先前预期保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168624894","title":"IDEAYA Biosciences将于五月启动RTOR申请，新药上市申请预计2026年下半年完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1168624894","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168624894?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:11","pubTimestamp":1777543916,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，公司计划于今年五月启动实时肿瘤学审评（RTOR）提交程序。这一重要举措标志着其候选药物开发进入关键阶段。\n根据最新时间表，IDEAYA Biosciences预计将在2026年下半年完成新药上市申请（NDA）的提交工作。该时间节点的确立为后续商业化进程奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179626267","title":"IDEAYA Biosciences飙涨逾40%！因眼癌药物组合试验达到主要目标并计划提交新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1179626267","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179626267?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:38","pubTimestamp":1776076736,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences今日盘前股价大幅上涨31.15%，引起了市场的广泛关注。独立中心影像评估确认，该组合疗法在主要疗效指标——中位无进展生存期方面展现出具有统计学意义的显著改善。具体数据显示，联合治疗组的中位生存期提高了6.9个月，而对照组仅为3.1个月，并且观察到了完全缓解病例。基于这些积极数据，公司计划在2026年下半年向美国食品药品监督管理局提交新药申请，寻求加速批准路径。","market":"nz","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"IDEAYA Biosciences飙涨逾40%！因眼癌药物组合试验达到主要目标并计划提交新药申请","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178706059","title":"IDEAYA与施维雅公布Darovasertib联合克唑替尼一线治疗HLA-A*02:01阴性转移性葡萄膜黑色素瘤的2/3期注册试验（OPTIMUM-02）积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1178706059","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178706059?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:07","pubTimestamp":1776074841,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences与施维雅联合宣布，其针对Darovasertib与克唑替尼组合疗法用于一线治疗HLA-A*02:01阴性转移性葡萄膜黑色素瘤的2/3期注册临床试验（OPTIMUM-02）取得积极顶线结果。该突破性进展标志着转移性葡萄膜黑色素瘤治疗领域迈出关键一步，为缺乏HLA-A*02:01基因型的患者群体提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175431474","title":"IDEAYA Biosciences临床试验达到主要终点 BICR评估显示中位无进展生存期实现统计学显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1175431474","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175431474?lang=zh_cn&edition=full","pubTime":"2026-04-13 18:01","pubTimestamp":1776074474,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布其临床试验成功达到主要研究终点。经独立中心影像评估确认，该研究在主要疗效指标——中位无进展生存期方面展现出具有统计学意义的显著改善。\n这一突破性进展标志着公司在靶向疗法开发领域取得重要里程碑，为后续临床开发计划的推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518127182","title":"IDEAYA生物科学盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518127182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518127182?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618519,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，IDEAYA生物科学股票出现异动，股价急速跳水5.04%。截至发稿，该股报17.53美元/股，成交量15.5541万股，换手率0.18%，振幅4.71%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.27%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4023","PARG","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516668860","title":"IDEAYA生物科学盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516668860?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:55","pubTimestamp":1741031723,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时55分，IDEAYA生物科学股票出现波动，股价大幅跳水5.06%。截至发稿，该股报19.53美元/股，成交量36.3073万股，换手率0.41%，振幅7.06%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.41%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","PARG","BK4023","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512464751","title":"IDEAYA生物科学2024财年实现净利润-2.74亿美元，同比减少142.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512464751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512464751?lang=zh_cn&edition=full","pubTime":"2025-02-20 12:01","pubTimestamp":1740024073,"startTime":"0","endTime":"0","summary":"2月20日，IDEAYA生物科学公布财报，公告显示公司2024财年净利润为-2.74亿美元，同比减少142.48%；其中营业收入为7.00百万美元，同比减少70.07%，每股基本收益为-3.36美元。从资产负债表来看，IDEAYA生物科学总负债64.94百万美元，其中短期债务298000.00美元，资产负债比为0.18，流动比率为0.15。机构评级：截至2025年2月20日，当前有12家机构对IDEAYA生物科学目标价做出预测，其中目标均价为50.92美元，其中最低目标价为27.00美元，最高目标价为62.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511826524","title":"IDEAYA生物科学盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511826524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511826524?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:26","pubTimestamp":1739460407,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时26分，IDEAYA生物科学股票出现波动，股价大幅下跌5.15%。截至发稿，该股报20.82美元/股，成交量14.152万股，换手率0.16%，振幅4.56%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.15%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172724045","title":"IDEAYA Biosciences 2024年第四季度GAAP每股亏损$(1.49)，低于预期$(0.64)，销售额$700万高于预期$467万","url":"https://stock-news.laohu8.com/highlight/detail?id=1172724045","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172724045?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:10","pubTimestamp":1739445025,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences报告季度每股亏损$，低于分析师一致预期的$，差距为132.81%。公司报告季度销售额为$700万，高于分析师一致预期的$467万，超出50.00%。相比去年同期的$392万，销售额增长了78.43%。以上内容来自Benzinga Earnings专栏，原文如下：$IDEAYA Biosciences$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 132.81 percent. This is a 186.54 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $7.00 million which beat the analyst consensus estimate of $4.67 million by 50.00 perc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"IDEAYA Biosciences 2024年第四季度GAAP每股亏损$(1.49)，低于预期$(0.64)，销售额$700万高于预期$467万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510332653","title":"IDEAYA生物科学盘中异动 大幅下挫5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510332653","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510332653?lang=zh_cn&edition=full","pubTime":"2025-02-12 01:05","pubTimestamp":1739293540,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日01时05分，IDEAYA生物科学股票出现异动，股价急速跳水5.22%。截至发稿，该股报21.25美元/股，成交量15.0055万股，换手率0.17%，振幅4.28%。IDEAYA生物科学股票所在的生物技术行业中，整体跌幅为1.74%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120105409881d742&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120105409881d742&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OCEA","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509235700","title":"IDEAYA生物科学盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509235700","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509235700?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:16","pubTimestamp":1738772167,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日00时16分，IDEAYA生物科学股票出现异动，股价大幅上涨5.06%。截至发稿，该股报25.33美元/股，成交量19.2119万股，换手率0.22%，振幅3.55%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为1.30%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020600160896191b56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025020600160896191b56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505784158","title":"IDEAYA生物科学盘中异动 临近收盘股价大涨5.00%报23.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505784158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505784158?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:54","pubTimestamp":1737492886,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时54分，IDEAYA生物科学股票出现波动，股价急速拉升5.00%。截至发稿，该股报23.29美元/股，成交量74.1109万股，换手率0.86%，振幅4.78%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为1.77%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122045446a22aa487&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122045446a22aa487&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IDYA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ideayabio.com","stockEarnings":[{"period":"1week","weight":-0.0463},{"period":"1month","weight":-0.0716},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.1823},{"period":"1year","weight":0.3435},{"period":"ytd","weight":0.0431}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"IDEAYA Biosciences, Inc.总部位于加利福尼亚州南旧金山，于2015年6月在特拉华州注册成立。该公司是一家专注于肿瘤学的精准医学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向疗法。他们的方法将识别和验证翻译生物标志物的广泛能力与小分子药物发现相结合，以选择最有可能从他们正在开发的靶向治疗中受益的患者群体。他们正在将这些能力应用于多类精准医学，包括直接靶向致癌途径和合成致死性，这代表了一类新兴的精准医学靶点。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.019424},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.055936},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.105822},{"month":4,"riseRate":0.428571,"avgChangeRate":0.062455},{"month":5,"riseRate":0.571429,"avgChangeRate":0.151132},{"month":6,"riseRate":0.75,"avgChangeRate":0.110114},{"month":7,"riseRate":0.5,"avgChangeRate":0.017276},{"month":8,"riseRate":0.375,"avgChangeRate":-0.012203},{"month":9,"riseRate":0.625,"avgChangeRate":0.093931},{"month":10,"riseRate":0.375,"avgChangeRate":-0.052852},{"month":11,"riseRate":0.857143,"avgChangeRate":0.118123},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016661}],"exchange":"NASDAQ","name":"IDEAYA Biosciences","nameEN":"IDEAYA Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"IDEAYA Biosciences,IDYA,IDEAYA Biosciences股票,IDEAYA Biosciences股票老虎,IDEAYA Biosciences股票老虎国际,IDEAYA Biosciences行情,IDEAYA Biosciences股票行情,IDEAYA Biosciences股价,IDEAYA Biosciences股市,IDEAYA Biosciences股票价格,IDEAYA Biosciences股票交易,IDEAYA Biosciences股票购买,IDEAYA Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}